1. Adams, JM, Harris, AW, Pinkert, CA, Corcoran, LM, Alexander, WS, Cory, S, Palmiter, RD & Brinster, RL (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538.
2. Adnane, J, Gaudray, P, Dionne, CA, Crumley, G, Jaye, M & Schlessinger, J (1991). BEK and FLG, two receptors to the members of the FGF family are amplified in subsets of human breast cancers. Oncogene 6: 659–663.
3. Aldaz, CM, Chen, T, Sahin, A, Cunningham, J & Bondy, M (1995). Comparative allelotype of in situ and invasive human breast cancer high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55: 3976–3981.
4. Berns, EMJJ, Klijn, JGM, van Putten, WLJ, van Staveren, IL, Portengen, H & Foekens, JA (1992). C-myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer. Cancer Res 52: 1107–1113.
5. Berx, G, Cleton-Jansen, A-M, Nollet, F, de Leeuw, WJF, van de Vijver, MJ, Cornelisse, CJ & van Roy, F (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO 14: 6107–6115.